A Study Of Galcanezumab In Participants With Episodic Cluster Headache

Trial ID or NCT#

NCT02397473

Status

recruiting iconRECRUITING

Purpose

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as Galcanezumab in participants with episodic cluster headaches.

Official Title

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache

Eligibility Criteria

Ages Eligible for Study: 18 Years to 65 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Have a diagnosis of cluster headache as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 beta guidelines with a history of episodic cluster headache with at least two cluster periods lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of >=1 month. - Participants are able to distinguish cluster headache attacks from other headaches.
Exclusion Criteria:
  1. - Current enrollment in or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device. - Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP) antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF). - Are taking indomethacin and/or are suspected of having another distinct trigeminal autonomic cephalalgia. - A history of migraine variants that could implicate or could be confused with ischemia. - Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins. - A history or presence of other medical illness that indicates a medical problem that would preclude study participation. - Evidence of significant active or unstable psychiatric disease, in the opinion of the investigator. - Women who are pregnant or nursing.

Contact us to find out if this trial is right for you.

Contact


650-723-5184